- Home
- RLTY vs BDSX Comparison
RLTY vs BDSX Comparison
Compare RLTY & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- BDSX
- Stock Information
- Founded
- RLTY 2022
- BDSX 2005
- Country
- RLTY United States
- BDSX United States
- Employees
- RLTY N/A
- BDSX N/A
- Industry
- RLTY Investment Managers
- BDSX Precision Instruments
- Sector
- RLTY Finance
- BDSX Health Care
- Exchange
- RLTY Nasdaq
- BDSX Nasdaq
- Market Cap
- RLTY 256.9M
- BDSX 194.9M
- IPO Year
- RLTY N/A
- BDSX 2020
- Fundamental
- Price
- RLTY $14.82
- BDSX $1.51
- Analyst Decision
- RLTY
- BDSX Strong Buy
- Analyst Count
- RLTY 0
- BDSX 4
- Target Price
- RLTY N/A
- BDSX $3.08
- AVG Volume (30 Days)
- RLTY 86.7K
- BDSX 332.5K
- Earning Date
- RLTY 01-01-0001
- BDSX 11-01-2024
- Dividend Yield
- RLTY 9.35%
- BDSX N/A
- EPS Growth
- RLTY N/A
- BDSX N/A
- EPS
- RLTY N/A
- BDSX N/A
- Revenue
- RLTY N/A
- BDSX $65,562,000.00
- Revenue This Year
- RLTY N/A
- BDSX $46.97
- Revenue Next Year
- RLTY N/A
- BDSX $30.43
- P/E Ratio
- RLTY N/A
- BDSX N/A
- Revenue Growth
- RLTY N/A
- BDSX 48.92
- 52 Week Low
- RLTY $11.38
- BDSX $1.11
- 52 Week High
- RLTY $14.60
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- RLTY 22.43
- BDSX 48.94
- Support Level
- RLTY $14.56
- BDSX $1.24
- Resistance Level
- RLTY $16.00
- BDSX $1.43
- Average True Range (ATR)
- RLTY 0.26
- BDSX 0.10
- MACD
- RLTY -0.14
- BDSX 0.01
- Stochastic Oscillator
- RLTY 2.44
- BDSX 64.44
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.